LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. [electronic resource]
Producer: 20121018Description: 158-69 p. digitalISSN:- 1532-6535
- Administration, Oral
- Adult
- Blood Glucose -- drug effects
- Diabetes Mellitus, Type 2 -- drug therapy
- Dose-Response Relationship, Drug
- Female
- Glucagon-Like Peptide 1 -- blood
- Glucose Tolerance Test
- Glycated Hemoglobin -- drug effects
- Glycosides -- administration & dosage
- Humans
- Hypoglycemic Agents -- adverse effects
- Intestinal Absorption
- Male
- Middle Aged
- Peptide YY -- blood
- Sodium-Glucose Transporter 1 -- antagonists & inhibitors
- Sodium-Glucose Transporter 2 Inhibitors
- Triglycerides -- blood
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.